Arthritis

The European Commission ( EC ) has granted marketing authorization for Hulio, a biosimilar to Humira ( Adalimumab ), for...


Findings from two phase 3 studies, COAST-V and COAST-W, in adults with ankylosing spondylitis ( AS ), also referred to...


Nail psoriasis is associated with functional impairment, pain and reduced quality of life. The aim of a study was to demonstrate...


Pain is one of the most important domains affecting health-related quality of life ( HRQoL ) in patients with psoriatic...


The purpose of the study was to describe the prevalence, clinical presentation, and management of rheumatic immune‐related adverse effects (...


A study has evaluated the effectiveness of oral Glucosamine in subgroups of people with hip or knee osteoarthritis ( OA...


Psoriatic arthritis ( PsA ) is an inflammatory arthropathy, associated with skin and/or nail psoriasis. Real world data on efficacy...


FKB327 ( Hulio ) is a proposed biosimilar of the Adalimumab Reference Product ( RP; Humira ). A randomized, double-blind,...


The European Commission ( EC ) has granted marketing authorisation for Olumiant ( Baricitinib ) 4 mg and 2 mg...


The FDA ( U.S. Food and Drug Administration ) has expanded the approved use of subcutaneous Actemra ( Tocilizumab )...


Results from the phase 3 SELECT-BEYOND clinical trial evaluating Upadacitinib ( ABT-494 ), an investigational oral JAK1-selective inhibitor, in patients...


Results from the phase 3 SELECT-MONOTHERAPY clinical trial were announced. This ongoing study evaluated Upadacitinib ( ABT-494 ), an investigational...


In a phase III, double-blind 24-week study, RA-BUILD, 684 biologic disease-modifying antirheumatic drug (DMARD)-naïve patients with rheumatoid arthritis and...


New data showing Secukinumab ( Cosentyx ) delivers sustained improvements in the signs and symptoms of psoriatic arthritis over three...


Results of the landmark PRECISION ( Prospective Randomized Evaluation of Celecoxib Integrated Safety vs Ibuprofen Or Naproxen ) trial demonstrated...


Women represent nearly 8 out of every 10 people with autoimmune diseases. Although the hugely disproportionate statistics are well known,...


A study has evaluated the magnitude of risk of cardiovascular and cerebrovascular morbidity in patients with psoriatic arthritis ( PsA...


Findings of a phase 3 study of patients with moderate to severe psoriasis demonstrating that nearly half of adult patients...


The increased rates of cardiovascular morbidity and mortality in patients with psoriasis are not adequately explained by traditional risk factors....


Cardiovascular disease ( CVD ) is the leading cause of death in rheumatoid arthritis ( RA ) patients. This study...